Danish immunoassay detection technology provider BluSense has collaborated with US-based big data solutions firm SystemOne to ensure quick detection and response in upcoming clinical trials for zika and dengue in Brazil and Malaysia.
Under the partnership, SystemOne will offer connectivity solutions to securely deliver important healthcare data from BluSense's diagnostic test devices to clinicians and health information systems.
The data from BluSense's BluBox diagnostic device will be integrated with SystemOne's data management platform called Aspect.
BluSense Diagnostics CEO Filippo Bosco said: "While our instrument generates critical data, we needed a partner to help us move, parse and channel the data to the right places to make the most difference.
“SystemOne, with its existing experience in dozens of countries, was the ideal partner to help us understand the best use cases for real-time information and for aggregated data."
Bosco added that SystemOne would also help them to discover "how to make the data flow in the most effective and least costly manner."
SystemOne is also developing an interface For BluSense customers to allow easy access and analysis of disease-related data.
The disease intelligence solution is set to be tested along with BluBox dengue assay in Malaysia and Brazil trials.
In addition to BluBox, BluSense is developing a new test to detect dengue virus using a single drop of blood, and an assay to identify the presence of Zika infection.
The latest collaboration is expected to allow BluSense to deliver real-time diagnostic data to health professionals and first responders.
SystemOne CEO Chris Macek noted: "By collaborating on the upcoming studies in Southeast Asia and Latin America, both companies bring core competencies to enable rapid detection and response to pandemic-prone diseases in high-risk regions of the world."
Image: BluBox sends diagnostic information to SystemOne's GxAlert platform. Photo: courtesy of PRNewsfoto/SystemOne.